Catalent Pharma Solutions Celebrates 75 Years of Softgel Innovation in 2009
Somerset, NJ, April 9, 2009
— Catalent Pharma Solutions, Inc., this year celebrates the seventy-fifth anniversary of the grant of the patent which revolutionized softgel manufacturing, and its seventy-five year heritage of continuous softgel innovation. Catalent will recognize this anniversary by offering a series of publications, technical seminars and celebrations throughout the year.
Softgel capsules encapsulate liquid, paste or oil-based active compounds in solution or suspension into an outer shell, which is sealed simultaneously with filling. Softgels have historically been used to solve formulation challenges, to improve clinical/patient performance of compounds, to provide safe handling for hormonal, potent and cytotoxic drugs, and to provide important market differentiation. Softgels are a preferred dose form in consumer/patient surveys, and physician research suggests that patient preferences may lead to improved medication adherence. Catalent provides softgels for prescription, over-the-counter, vitamin/mineral/supplement, and cosmetic/cosmeceutical customers and applications.
The ground-breaking patent, granted to Robert Pauli Scherer in August 1934, established a new way to manufacture softgels using a rotary die process. This new approach dramatically improved quality and exponentially increased output, while at the same time significantly lowering costs versus the prior method of making capsules, patented one hundred years earlier. Mr. Scherer established a company in Detroit to commercialize the technology, known as Gelatin Products Corporation, which in 1947 was renamed R.P. Scherer Corporation.
Today, Catalent’s Oral Technologies segment carries forward the R.P. Scherer heritage of both scientific and manufacturing innovation, with more than 600 currently active softgel patents and patent applications. Catalent most recently launched a next generation capsule shell, Vegicaps® capsule, produced completely from plant-derived materials, which further expanded softgel compatibility, and addressed the needs of specific patient/consumer sub-populations.
Thomas Stuart, Group President of Catalent’s Oral Technologies business, said, “We’re pleased to have reached this important milestone for the technology and the business. Since I joined the former R.P. Scherer in 1990, we’ve introduced many important formulation and manufacturing innovations for the softgel platform. Even more importantly, during this same time we have brought to market hundreds of important pharmaceutical and consumer health products for our customers, which have improved the lives of patients/consumers around the world.”
Stuart continued, “We expect that the softgel platform’s proven advantage in delivering compounds with limited aqueous solubility will be increasingly valuable to drug developers, and that the consistently proven patient/consumer preference for softgels will be increasingly important for clinical and marketing purposes. And we believe that Catalent’s long heritage of experience, know-how and expertise in formulation and manufacturing, combined with our unrelenting focus on meaningful softgel innovation, will continue to make Catalent the industry’s preferred softgel partner in the future.”
For more information about Catalent’s softgel offerings, or about our 75th Anniversary-related activities, visit www.catalent.com/softgel75 .
Headquartered in Somerset, New Jersey, Catalent Pharma Solutions is a leading provider of advanced dose form and packaging technologies, and development, manufacturing and packaging services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes. Catalent employs approximately 9,100 at more than 30 facilities worldwide and in fiscal 2008 generated more than $1.8 billion in annual revenue. For more information, visit www.catalent.com .